Additionally, although elevated levels of TNF-α and IFN-γ contribute to lung damage and high case fatality in COVID-19 patients, combination therapy of anti-TNF-α and anti-IFN-γ neutralizing antibodies effectively reduces inflammatory cell death, tissue damage, and mortality (58). The gene discussed is IFNG; the disease is COVID-19.